Cargando…

Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis

Glycemic variability (GV) has been an emerging target for preventing complications related to type 2 diabetes. For reducing GV, DPP-IV inhibitors have shown effectiveness compared to other oral anti-hyperglycemic drugs (OADs), but systematic evaluation has yet to be existed. A systematic review and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Subin, Lee, Heeyoung, Kim, Yoonhye, Kim, EunYoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746852/ https://www.ncbi.nlm.nih.gov/pubmed/31527625 http://dx.doi.org/10.1038/s41598-019-49803-9

Ejemplares similares

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

MON-653 The Effects of DPP IV Inhibitor on Glycemic Variability in Type 2 Diabetic Patients Treated with Twice Daily Premixed Human Insulin
por: Tan, Florence Hui Sieng, et al.
Publicado: (2020)

Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis
por: Oh, SuA, et al.
Publicado: (2021)

Genetic variation in DPP-IV gene linked to predisposition of T2DM: A case control study
por: Bhargave, Archna, et al.
Publicado: (2022)

Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI
por: Xue, Jujun, et al.
Publicado: (2020)

Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis
por: Oh, SuA, et al.
Publicado: (2022)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
por: Kim, Sang-Yong, et al.
Publicado: (2022)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
por: Del Prato, Stefano, et al.
Publicado: (2017)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
por: Saini, Kunika, et al.
Publicado: (2023)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
por: Liu, Dan, et al.
Publicado: (2019)

Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
por: Zein, Ahmad Fariz Malvi Zamzam, et al.
Publicado: (2022)

Real-world safety evaluation of musculoskeletal adverse events associated with Korean pediatric fluoroquinolone use: a nationwide longitudinal retrospective cohort study
por: Kim, Yoonhye, et al.
Publicado: (2019)

Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
por: Lee, Young Ki, et al.
Publicado: (2013)

The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin*
por: Tan, Florence Hui Sieng, et al.
Publicado: (2021)

DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
por: Ejikeme, Chidinma, et al.
Publicado: (2021)

Paeoniflorin ameliorates glycemic variability-induced oxidative stress and platelet activation in HUVECs and DM rats
por: Huang, Ye, et al.
Publicado: (2020)

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
por: Kim, Kyuho, et al.
Publicado: (2021)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Virtual Screening, Synthesis, and Biological Evaluation of Some Carbohydrazide Derivatives as Potential DPP-IV Inhibitors
por: Jadhav, Prerana B., et al.
Publicado: (2022)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Wang, Qixian, et al.
Publicado: (2018)

Effects of DPP4 Inhibitors on Renal Outcomes in Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Dalui, Saikat K., et al.
Publicado: (2021)

Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and meta-analysis
por: Yuan, Xiaojie, et al.
Publicado: (2020)

Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study)
por: Bae, Ji Cheol, et al.
Publicado: (2022)

Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients
por: Chen, Hsin-Hung, et al.
Publicado: (2015)

Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
por: Ansarullah,, et al.
Publicado: (2013)

Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis
por: Purja, Sujata, et al.
Publicado: (2021)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial
por: Yin, Ting-Ting, et al.
Publicado: (2018)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
por: Chhabria, Srishti, et al.
Publicado: (2022)

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
por: Kim, Sun Woo
Publicado: (2010)

Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses
por: Kim, Bo-Ram, et al.
Publicado: (2018)

Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
por: Chong, Shiau Chin, et al.
Publicado: (2022)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
por: Choe, Eun Yeong, et al.
Publicado: (2014)

High glycemic albumin representing prestroke glycemic variability is associated with hemorrhagic transformation in patients receiving intravenous thrombolysis
por: Lee, Sang-Hwa, et al.
Publicado: (2022)

Topical ocular administration of DPP-IV inhibitors: a new approach for treating diabetes-induced retinal neurodegeneration
por: Simó, Rafael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gllkn90jqq5q1t4h1smsvl0865